Loading, Please Wait...
RALEIGH, N.C., May 14, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. is pleased to announce it has received an array of awards and recognition during the first months of 2019.
On Saturday, May 4, PRA was recognized as the Clinical Research Company of the Year – the Americas by PharmaTimes. This is the seventh consecutive year that the company has won this prestigious industry award.
Clinical Researcher of the Year – The Americas is a real-world competition that recognizes the talent and passion of industry and academic researchers and is considered a key barometer of quality standards in the clinical research organization (CRO) industry. The multi-stage competition is organized by an independent executive steering committee comprised of senior industry leaders from big and small pharma, leading CROs, and professional membership associations.
PRA accepted this honor during an awards ceremony in Boston, MA.
In April, PRA was also named on the Forbes 2019 Best Large Employers list, which recognizes the companies that have been identified as being most liked by employees. Additionally, this past January, PRA was named one of the best employers for diversity by Forbes. This ranking recognizes organizations that successfully cultivate cultures that welcome and support all workers. Forbes partnered with market research company Statista to create these annual rankings.
“PRA is very proud of the recognition we have received in recent days,” said Colin Shannon, PRA’s Chief Executive Officer. “It is gratifying to once again be recognized by our peers for our commitment to improving and saving lives through new and innovative treatments.”
ABOUT PRA HEALTH SCIENCES
PRA Health Sciences is a full-service global contract research organization, providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA’s integrated services include data management, statistical analysis, clinical trial management, medical writing and regulatory and drug development consulting. PRA’s global operations span more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 15,800 employees worldwide. Since 2000, PRA has participated in approximately 3,700 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 75 drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES: Kate Reilly, Strategic Communications Specialist, Global Marketing & Innovation
EMAIL: ReillyKate@prahs.com PHONE: +1 919.786.8510